Immunologic deficiency syndrome
Drug research and approvals for immunologic deficiency syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 438 studies of immunologic deficiency syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 438
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy ComparatorsNCT07948772 · Not reported · Insmed Incorporated · starts Jun 30, 2026
- Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human…NCT07932132 · Phase 4 · Liaoning Chengda Biotechnology CO., LTD · starts Aug 8, 2026
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07925307 · Not applicable · University of California, San Diego · starts Oct 16, 2026
- Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir AlafenamideNCT07921472 · Not reported · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · starts May 19, 2026
- Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral TreatmentNCT07903441 · Phase 2 · Federal University of São Paulo · starts Aug 1, 2026
- A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming…NCT07850609 · Phase 2 · Merck Sharp & Dohme LLC · starts Oct 27, 2026
- El Camino HIV Prevention and Care StudyNCT07834853 · Not applicable · American University · starts Jul 16, 2026
- Open-label Gene Therapy Study in p47-CGDNCT07826767 · Phase 1 / Phase 2 · Somagenetix AG · starts Aug 18, 2026
- A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsNCT07818915 · Phase 1 · ViiV Healthcare · starts Sep 15, 2026
How its trials ended
773 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 178 whose ending is known, 62% met their primary endpoint, 4% missed it and 33% stopped early.
- Completed, result not reported38750%
- Ongoing13417%
- Met its primary endpoint11114%
- Status unknown7410%
- Stopped: other or unclear314%
- Stopped: enrollment or feasibility111%
- Missed its primary endpoint81%
- Stopped: sponsor or business decision61%
- Stopped: lack of efficacy51%
- Stopped: funding41%
- Stopped: safety2<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA